HLA-A and toxic epidermal necrolysis: Considering the neurological disorders persistence and the lack of responsiveness to mannitol, carbamazepine (400 mg/day) was started at week seven, once HLA-A*3101 hyper-sensibility was excluded (in order to avoid a hypersensitivity reaction, Stevens–Johnson syndrome, toxic epidermal necrolysis, or death of the patient) [53].